Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | IDO1 | P14902 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MC4R | P32245 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434773 | 0.87 | LMNA (0.68) | LMNAHSD17B10CHRM1MAPTKDM4E | |
| SCHEMBL9277493 | 0.87 | LMNA (0.71) | LMNAHSD17B10CHRM1MAPTKDM4E | |
| SCHEMBL9518202 | 0.84 | IDO1 (0.54) | LMNAIDO1HSD17B10CHRM1MAPT | |
| SCHEMBL4143905 | 0.83 | LMNA (0.71) | LMNAHSD17B10MAPTKDM4EMEN1 | |
| SCHEMBL6420408 | 0.83 | LMNA (0.66) | LMNAHSD17B10MAPTKDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL9096753 | 0.82 | LMNA (0.69) | LMNAHSD17B10MAPTKDM4EMEN1 | |
| SCHEMBL6421876 | 0.81 | LMNA (0.64) | LMNAHSD17B10MAPTKDM4EMEN1 | |
| SCHEMBL30092456 | 0.81 | TACR1 (0.49) | LMNAIDO1HSD17B10CHRM1MAPT | |
| SCHEMBL7280926 | 0.81 | LMNA (0.68) | LMNAHSD17B10MAPTKDM4EMEN1 | |
| SCHEMBL4463271 | 0.81 | LMNA (0.68) | LMNAHSD17B10MAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230032216-A1 | INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER | Deutsches Krebsforschungszentrum Stiftung des oeffentlichen Rechts Im Neuenheimer Feld 280 (DE) | 2023-02-02 | — | — | US | claimed |
| EP-4073273-A1 | INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2022-10-19 | — | — | EP | claimed |
| CN-114901837-A | Interleukin-4 inducible gene 1(IL4I1) and corresponding metabolites as biomarkers for cancer | 德国癌症研究公共权益基金会 | 2022-08-12 | — | — | CN | claimed |
| WO-2021116357-A1 | INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2021-06-17 | — | — | WO | claimed |
| US-20230032216-A1 | INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER | Deutsches Krebsforschungszentrum Stiftung des oeffentlichen Rechts Im Neuenheimer Feld 280 (DE) | 2023-02-02 | — | — | US | disclosed |
| EP-4073273-A1 | INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2022-10-19 | — | — | EP | disclosed |
| CN-114901837-A | Interleukin-4 inducible gene 1(IL4I1) and corresponding metabolites as biomarkers for cancer | 德国癌症研究公共权益基金会 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021116357-A1 | INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2021-06-17 | — | — | WO | disclosed |
| US-20210023034-A1 | PHENYLALANINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2021-01-28 | — | — | US | disclosed |
| WO-2019185907-A1 | PHENYLALANINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS | UNIVERSITE PARIS EST CRETEIL VAL DE MARNE (FR) | 2019-10-03 | — | — | WO | disclosed |
| EP-0266950-B1 | Nor-statine and nor-cyclostatine polypeptides | PFIZER (US) | 1993-12-29 | — | — | EP | disclosed |
| US-5034376-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1991-07-23 | — | — | US | disclosed |
| US-4935405-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1990-06-19 | — | — | US | disclosed |
| US-4814342-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1989-03-21 | — | — | US | disclosed |
| EP-0266950-A2 | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023034-A1 | PHENYLALANINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS | IL4I1, PAH, IL4 | LMNA 4429/4885IDO1 82/4885HSD17B10 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.